Numerous studies over the past decades have targeted PC biology and uncovered mutations in KRAS, p53, cyclin-dependent kinase inhibitor 2A (CDKN2A), and SMAD4 and their signaling pathways. This evidence concerns the gene TP53 and pachyonychia congenita.